Citius Oncology, Inc. (CTOR) Stock Overview
Explore Citius Oncology, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Citius Oncology, Inc. (CTOR)
Key Financials
Key Financials
Market Cap
71.6M
P/E Ratio
-1.70
EPS (TTM)
$-0.47
ROE
-1.03%
CTOR Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Citius Oncology, Inc. (NASDAQ: CTOR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Citius Oncology, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CTOR on the NASDAQ shows an RSI of 35.74, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.
Key metrics behind Citius Oncology, Inc.'s NASDAQ-traded stock include a P/E ratio of -1.70 and a market capitalization of 71.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CTOR on the NASDAQ.